氨酸抑制剂:目前的作用,毒性管理和免疫抑制的未来边界
Ayush Mistry1, Anwesha Bhattacharya1, Moitri Mondal1
1Department of Pharmacy, Calcutta Institute of Pharmaceutical Technology and Allied Health Science, Howrah, 711316, India.
Molecular neurobiology
|December 8, 2025
概括
像环素这样的氨酸抑制剂 (CNIs) 通过抑制T细胞激活来抑制免疫系统,这对于移植和自身免疫性疾病至关重要. 然而,CNI会引起显著的副作用,需要仔细监测和风险管理.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸抑制剂 (CNIs) 是一种强大的免疫抑制剂,用于器官移植和自身免疫性疾病.
- CNI通过抑制氨酸酸酶通路而起作用,从而损害T细胞激活.
研究的目的:
- 审查氨酸抑制剂 (CNIs) 的机制,临床应用和安全问题.
- 探索未来的方向,以更安全,更有针对性地使用CNI.
主要方法:
- 这篇叙事综述综合了关于CNI的现有文献.
- 涵盖的关键方面包括CNI机制,应用和不良影响.
主要成果:
- CNI有效地抑制T细胞激活,这对于治疗移植和自身免疫性疾病至关重要.
- 常见的副作用包括毒性,高血压,神经毒性和代谢障碍,需要持续监测药物和风险因素管理.
结论:
- 虽然CNI是必不可少的免疫抑制剂,但它们会带来严重的安全风险.
- 未来的研究应该专注于开发更安全,更有针对性的CNI疗法和改进的患者监测策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450
Chronic Kidney Disease III: Interprofessional Care
323
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
323
Chronic Kidney Disease IV: Nursing Management
299
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
299
Nephrotic Syndrome III : Nursing Management
271
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
271
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
457
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457


